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Objectives: Enteroaggregative Escherichia coli (EAEC) was recently reported as
a major diarrheagenic pathogen in infant and adult travelers, both in developing
and developed countries. EAEC strains are known to be highly resistant to anti-
biotics including quinolones. Therefore in this study we have determined the
various mechanisms of quinolone resistance in EAEC strains isolated in Korea.
Methods: For 26 EAEC strains highly resistant to fluoroquinolone, minimal
inhibitory concentrations for fluoroquinolones were determined, mutations in
the quinolone target genes were identified by PCR and sequencing, the presence
of transferable quinolone resistance mechanism were identified by PCR, and the
contribution of the efflux pump was determined by synergy tests using a proton
pump inhibitor. The expression levels of efflux pump-related genes were iden-
tified by relative quantification using real-time PCR.
Results: Apart from two, all tested isolates had common mutations on GyrA
(Ser83Leu and Ser87Gly) and ParC (Ser80Gln). Isolates EACR24 and EACR39 had
mutations that have not been reported previously: Ala81Pro in ParC and Arg157Gly
in GyrA, respectively. Increased susceptibility of all the tested isolates to cipro-
floxacin and norfloxacin in the presence of the pump inhibitor implies that efflux
pumps contributed to the resistance against fluoroquinolones. Expression of the
efflux pump-related genes, tolC, mdfA, and ydhE, were induced in isolates EACR
07, EACR 29, and EACR 33 in the presence of ciprofloxacin.
Conclusion: These results indicate that quinolone resistance of EAEC strains
mainly results from the combination of mutations in the target enzyme and an
increased expression of efflux pump-related genes. The mutations Ala81Pro in
ParC and Arg157Gly in GyrA have not been reported previously; the exact
influence of these mutations should be investigated further.ted under the terms of the Creative Commons Attribution Non-Commercial License (http://
0) which permits unrestricted non-commercial use, distribution, and reproduction in any
roperly cited.
ase Control and Prevention. Published by Elsevier Korea LLC. All rights reserved.
240 J.-Y. Kim, et al1. Introduction
The antibiotic susceptibility of these isolates was per-Enteroaggregative Escherichia coli (EAEC) is one of
the diarrheagenic E. coli strains, and its importance in
public health is increasing around the world [1]. EAEC
has been implicated as major etiologic pathogens of
infant gastroenteritis in developing countries, and asso-
ciated with persistent diarrhea longer than 14 days,
which is related to high mortality in these regions [2,3].
It was recently also reported to be one of the major
diarrheagenic pathogens in young children and adults
traveling in developed countries [4].
EAEC is defined by "stacked-brick" type aggregative
adherence to HEp-2 cells. The pathogenesis of EAEC
infection is not fully understood but it is presumed to
result from the characteristic that it adheres to the
intestinal mucosa using adherence fimbriae, and causes
damage to the mucosal epithelium [2,5,6]. The putative
virulence factors are mostly in the 60e65 MDa aggre-
gative adherence plasmids [1,7].
The ratio of antibiotic resistant strains in EAEC is
higher than in other diarrheagenic E. coli strains. In Peru,
the antibiotic resistance ratio of diffuse adhering E. coli
andEAECwas higher than that of otherE. coli strains, and,
in Iran, the EAEC isolates showed 100% resistance to
ampicillin, and 64.3%, 57.1%, and 42.9% to tetracyclin,
nalidixic acid and ciprofloxacin (CIP), respectively [8,9].
Generally, EAEC strains are highly resistant to
ampicillin, nalidixic acid, cotrimoxazol, and others. It is
presumed that persistent diarrhea increases the chance of
EAEC being exposed to the various antibiotics caused
the highly antibiotic resistant nature of EAEC [9].
Quinolone resistance in enteric bacteria is mainly
a result of mutations in the target genes of quinolone
encoding DNA gyrase and topoisomerase IV [10], and
by the active efflux of quinolone. These resistance
mechanisms cannot be transmitted to other bacteria, but
recently a transferable quinolone resistance mechanism,
qnr, has been reported [11]. It has also been reported that
quinolone resistance often results from the combination
of target alteration and active efflux pumps in enteric
bacteria [12e14]. In a previous study, we reported that
the efflux system including MdfA is involved in qui-
nolone resistance in Shigella flexneri [15]. The contri-
bution of the efflux system to quinolone resistance in
E. coli isolated in the USA has been also reported [3].
In this study, we have determined the mechanism of
quinolone resistance resulting from the presence of
target alteration, efflux pump, and other transferrable
mechanisms in EAEC strains isolated in Korea.2. Materials and Methods
2.1. Bacterial isolates
We received 227 clinical EAEC isolates from the
national public health network of Korea in 2008e2009.formed by the disk diffusion test, according to the
Clinical and Laboratory Standards Institute (CLSI)
guidelines [16]. We selected 26 EAEC isolates showing
high resistance to CIP (inhibitory zone was <6 mm).
2.2. Determination of minimum inhibitory
concentrations
The minimum inhibitory concentrations (MICs) of
CIP and norfloxacin (NOR) were determined by E-test
(AB Biodisk, Solna, Sweden) according to the manu-
facturer’s instruction. E. coli ATCC 25922 was used as
a quality assurance strain [16,17]. CLSI criteria were
used to categorize strains as susceptible, intermediate, or
resistant [16].
2.3. DNA sequence analysis of the quinolone
resistance-determining regions
The quinolone resistance-determining regions
(QRDRs) of gyrA, gyrB, parC, and parE genes were
amplified by PCR [15] and sequenced using an ABI
3700 sequencer (Applied Biosystem, Foster, CA, USA).
These portions of the QRDRs corresponded to amino
acid residues 54e171 of GyrA, 397e520 of GyrB,
12e130 of ParC, and 421e524 of ParE.
2.4. Amplification of qnrA, qnrB, qnrS, and
aac(60)-Ib-cr genes
Protocols for the amplification of qnrA, qnrB, qnrS, and
aac(60)-Ib-cr genes have been previously described [15].
The PCR was performed in a final volume of 25 mL con-
taining 2 ı`L of template DNA, 1 reaction buffer, 0.2mM
of each deoxynucleoside triphosphate, 20 pM of each
primer, and 3.5 units of Taq polymerase. The assays were
performed in a Peltier Thermal Cycler (MJ Research,
Waltham, MA, USA) under the following conditions: one
cycle of 94 C for 5minutes followed by 30 cycles of 94 C
for 1 minute, 60 C for 1 minute, and 72 C for 1 minute
and a final extension of 72 C for 5 minutes.
2.5. Synergy tests
Synergy experiments were performed using the flu-
oroquinolones CIP and NOR, and the efflux pump
inhibitor, reserpine. Reserpine was added in Muller-
Hinton agar at the concentration of 100s added in
Muller-Hin testing to CIP and NOR by E-test was per-
formed in agar plates with or without reserpine [17,18].
2.6. Expression of mdfA, tolC, and ydhE
The expression of each gene was investigated using
real-time PCR as described previously [15]. The cycling
conditions were 40 cycles of 95 C for 15 seconds fol-
lowed by 60 C for 1 minute. Quantification was based
on the threshold cycle value, which was determined with
the aid of the SDS 2.1 software system (Applied Bio-
systems). Relative gene expression level was calculated
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DDCT Z DCT (sample)  DCT (control), and DCT is
the CT of the target gene subtracted from the CT of the
housekeeping gene [19]. All tests were repeated five
times and the relative gene expression value is indicated
average of five tests. Relative gene expression level of
efflux pump related genes were compared with those of
the quinolone susceptible strain E. coli ATCC 25922.3. Results
3.1. Susceptibility of Shigella isolates to
fluoroquinolones
All of the 26 EAEC isolates were found to be
highly resistant to the fluoroquinolones tested: CIP
(MIC, 32e256 mg/mL), and NOR (MIC ranges of
32e256 mg/mL).
3.2. Mutations in the genes gyrA and parC
From the sequence analysis of fluoroquinolone
resistance-related genes, there were no alterations of
amino acid sequence in GyrB and ParE, while several
mutations were detected in the GyrA and ParC (Table 1).
Seventeen isolates among the tested fluoroquinolone
resistance isolates had multiple mutations in
GyrA (Ser83Leu and Ser87Gly) and ParC (Ser80Gln
and Glu84Val or Gly). Seven isolates were observed
to have double mutations in GyrA (Ser83Leu and
Ser87Leu) and one in ParC (Ser80Gln). The combination
of GyrA gene (Ser83 and/or Asp87) and ParC gene (Ser80
and/or Glu84) were frequently found in fluoroquinolone
highly resistant isolates. However, fluoroquinolone
resistant isolates EACR 24 and 39 were found to have
novel mutations in ParC and GyrA, respectively. EACR
24 contained two substitutions, one in GyrA (Ser83Leu)
and one in ParC (Ala81Pro; GenBank No. EU512995).
EACR 39 exhibited four substitutions, three in GyrA
(Ser83Leu, Asp87Gly, Arg157Gly; GenBank No.
HM753589) and ParC (Ser80Gln). The mutations
Arg157Gly in GyrA and Ala81Pro in ParC have not been
reported previously. There was no notable difference in
MIC for CIP and NOR between the triple and quadruple
mutants.
3.3. Presence of qnrA, qnrB, qnrS, and aac(60)-
Ib-cr genes
Among the 26 fluoroquinolone resistant isolates,
qnrA was only detected in EACR 33. Three isolates
(EACR 25, 29, and 32) were PCR positive for aac(60)-
Ib-cr. However, qnrB and qnrS were not identified in
any of the tested fluoroquinolone resistant isolates.
3.4. Involvement of putative efflux pumps for
fluoroquinolone resistance
To elucidate the involvement of the efflux pump in
floroquinolone resistance in EAEC isolates, synergyexperiments were performed using the efflux pump
inhibitor, reserpine and the fluoroquinolones CIP and
NOR. The MICs for 26 isolates of fluoroquinolones
were decreased 32- to 256-fold in agar plate containing
reserpine in comparison with those observed in
reserpine-free medium (Table 1).
3.5. Expression of genes, mdfA, tolC, and ydhE,
encoding efflux pump
EACR07, EACR29, and EACR33 were selected to
investigate the extent of intervention of efflux pump in
fluoroquinolone resistance, because EACR07 and
EACR29 showed different MIC for fluoroquinolones but
had same mutation profile on quinolone target enzyme,
and EACR29 and EACR31 showed a similar MIC but
have different mutation profiles. Real-time PCR showed
that isolates EACR07, EACR29, and EACR33 exhibited
approximately 9 times higher expression of tolC, mdhA,
and ydhE, respectively, than the E. coli ATCC 25922
control strain (Figure 1). When CIP was added to
medium, the expression of the three genes were greatly
increased in all three isolates. The EACR07 isolate
expressed 57.33 times more tolC, 2.9 times more mdfA,
and 5.8 times more ydhE than the control strain.
EACR29 exhibited 143.2 times more tolC, 9.7 times
more mdfA, and 13.6 times more ydhE than the control
strain. EACR33 exhibited 180.8 times more tolC, 6.3
times more mdfA, and 12.9 times more ydhE than the
control strain.
4. Discussion
EAEC is a main cause of persistent diarrhea in
children in developing regions and a prevalent cause of
traveler’s diarrhea. Recently it was reported that EAEC
also can cause acute diarrhea in children in both
developing and industrialized countries [4]. Because of
this, even though the EAEC was most recently catego-
rized as diarrheagenic E. coli, it became an emerging
enteric pathogen.
EAEC is also known to have relatively high resis-
tance to b-lactams and quinolones compared with other
E. coli because it has repeated exposure to antimicrobial
agent or may interact with other resistant flora that cause
chronic diarrhea [8].
In this study, 26 EAEC clinical isolates with high
resistance to fluoroquinolones were examined to identify
their quinolone resistance mechanism. Resistance to
quinolones is usually due to mutations of the bacterial
targets, DNA gyrase and topoisomerase IV [10]. In this
study, all tested isolates had multiple mutations on GyrA
and ParC at the QRDR of each.
Apart from EACR24 and EACR 39, all tested isolates
had the common mutations on GyrA (Ser83Leu and
Ser87Gly) and ParC (Ser80Gln). Seventeen isolates had
double mutations on both GyrA and ParC, seven isolates
Table 1. Characteristics of EAEC isolates with resistance to fluoroquinolones
Strain no.
MIC (mg/mL) gyrA amino acid at codon parC amino acid at codon
qnr, aac(6’)Ib-cr,
qepA typeCIP
CIP þ
Reserpine Nor
Nor þ
Reserpine
83 87 157 80 81 84
GAC
(Asp)
GAC
(Asp)
CGT
(Arg)
AGC
(Ser)
GCC
(Ala)
GAA
(Glu)
EACR01 64 <2 32 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d -T-(Val)
EACR02 64 <2 32 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d -T-(Val)
EACR03 64 <2 32 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d -T-(Val)
EACR04 64 <2 32 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d -T-(Val)
EACR05 64 <2 32 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d -T-(Val)
EACR06 64 <2 32 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d -T-(Val)
EACR07 64 <2 32 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d d
EACR09 64 <2 32 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d -T-(Val)
EACR10 64 <2 32 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d -T-(Val)
EACR11 64 <2 32 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d -T-(Val)
EACR12 64 <2 32 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d -T-(Val)
EACR15 32 <2 32 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d d
EACR17 32 <2 32 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d -T-(Val)
EACR18 64 <2 32 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d -T-(Val)
EACR21 64 <2 32 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d -T-(Val)
EACR22 64 <2 32 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d -T-(Val)
EACR23 64 <2 32 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d -T-(Val)
EACR24 32 <2 32 <2 -T-(Leu) d d d C–(Pro) d
EACR25 128 <2 32 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d d aac(6’) Ib-cr
EACR29 256 <2 64 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d d aac(6’) Ib-cr
EACR31 256 <2 64 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d d
EACR32 128 <2 64 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d d aac(6’) Ib-cr
EACR33 <256 <2 256 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d -G-(Gly) qnrA
EACR38 128 <2 32 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d d
EACR39 128 <2 64 <2 -T-(Leu) -G-(Gly) G–(Gly) -AG(Gln) d d
EACR41 64 <2 32 <2 -T-(Leu) -G-(Gly) d -AG(Gln) d -G-(Gly)
Each value is the average of five replicates.
CIP Z ciprofloxacin; NOR Znorfloxacin.
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ParC. In EACR 39, we found a substitution of arginine
to glycine at Codon 157 in GyrA, which has not been
reported previously. This mutation, however, is
presumed to contribute insignificantly to the resistance,
because the MIC for fluoroquinolone is similar to that of
other resistant strains that have the same mutations apart
from Arg157Gly in GyrA. In EACR24, we also found
a mutation that has not been reported before: Ala81Pro
in ParC. The MIC value for CIP of EARC24 was 32 mg/
mL, and it had two mutations in the target genes GyrAFigure 1. Expression of tolC, mdfA, and ydhE measured by RT-P
the average of five culture replicates, each of which was evaluat
2DDCT, where DDCT Z DCT (sample)  DCT (control) [3]. CTand ParC; therefore, this newly reported mutation seems
to have a great impact on fluoroquinolone resistance.
The exact influence of these two newly reported muta-
tions should be investigated further.
In general, reduced susceptibility due to a change of
Ser83 in GyrA leads to an increase in resistance with the
addition of one or two mutations in GyrA or ParC [20].
However, there was no comparable difference in MICs
for CIP and NOR. For example, EACR07 and EACR29
have the same mutation profile, two in GyrA and one in
ParC, but the MIC of CIP was 64 mg/mL for EACR04CR in the absence and presence of ciprofloxacin. Each value is
ed twice. Relative gene expression levels were calculated as
Z threshold cycle.
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that other resistance mechanisms such as efflux are
concerned with these isolates.
Efflux pumps utilize the energy of the proton motive
force to transport out the antibiotics out of cells [21]. In
all the 26 isolates, the contribution of efflux pump to
fluoroquinolone resistance was determined, because
increased susceptibility of all the tested isolates to CIP
and NOR in the presence of a proton pump inhibitor
implied the presence of energy-dependent active efflux
pumps for fluoroquinolones. The loss of multidrug
efflux could neutralize the resistance contributed by
target site alteration as has been shown in E. coli,
Shigella, and Salmonella typhimurium [12,14,15].
Expression of tolC for resistance-nodulation-cell
division superfamily transporter, mdfA for major facili-
tator superfamily transporter, and ydhE for multi-
antimicrobial extrusion protein family transporter was
tested in EACR07, EACR29, and EACR 33. There was
a clear relationship between increased expression of
genes for efflux pumps and resistance to fluoroquinolone
in all three isolates. Expression of tolC, mdfA, and ydhE
was greatly induced in the presence of ciprofloxacin, but
the extent was different from the tested isolates. EACR33
produced the largest amount of tolC in the presence of
ciprofloxacin, and it has highest MIC value for fluo-
roquinolones among the tested isolates. However, the
expression level of mdfA and ydhE was less than that of
EACR24. This can be explained by previous reports that
the fluoroquinolone efflux pump of E. coli is mainly
encoded by acrAB and tolC genes [22,23] EACR29
produced 2.3e3.3 times more transporters than EACR07
in the presence of ciprofloxacin. This may explain the
difference in MICs between the isolates that have the
same mutation profile on the target enzyme. In conclu-
sion, these results indicates that resistance to fluo-
roquinolones resulted from both the presence of target site
mutations and the expression of genes for efflux pumps.
In recent studies, the qnrA, B, S and aac(60)Ib-cr
genes were shown to be related to quinolone resistance
[11]. We detected aac(60)Ib-cr genes in EACR29, and in
qnrA, EACR33. Therefore, further studies are needed to
determine whether the expression of these genes
contribute to fluoroquinolone resistance. To our
knowledge, this is the first report of the mutations
Ala81Pro in ParC and Arg157Gly in GyrA.
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